Invesco BLDRS Europe Select ADR Index Fund

Latest Invesco BLDRS Europe Select ADR Index Fund News and Updates

  • uploads///Chart
    Company & Industry Overviews

    A Closer Look at Novartis’s Innovative Medicines Segment

    Novartis’s Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Novartis ADR’s Performance and Revenue Estimates for Q3 2018

    Novartis’s (NVS) stock price has increased ~14.3% in the third quarter, and its stock rose ~2.8% year-to-date on October 2.

    By Mike Benson
  • uploads///business _
    Miscellaneous

    Novartis to Divest Portions of Sandoz US to Aurobindo

    Novartis (NVS) announced today that it has agreed to sell select portions of its Sandoz US portfolio to Aurobindo Pharma USA.

    By Mike Benson
  • uploads///doctor _
    Company & Industry Overviews

    EC Approves GSK’s Nucala for Children with Severe Asthma

    On August 30, GlaxoSmithKline (GSK) announced that the EC approved Nucala for pediatric patients with severe refractory eosinophilic asthma.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Novartis’s Sandoz in Q2 2018

    Novartis’s (NVS) Sandoz reported nearly flat revenues at ~$2.46 billion in Q2 2018 compared to $2.45 billion in the second quarter of 2017.

    By Mike Benson
  • uploads///blood _
    Company & Industry Overviews

    Novartis’s SOLAR-1 Trial Met Primary Endpoint

    Novartis (NVS) announced on August 23 that its SOLAR-1 trial evaluating alpelisib combined with fulvestrant has met its primary endpoint.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2

    GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes its wellness, oral health, nutrition, and skin health products.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Novartis’s Alcon Performed in 4Q17

    Alcon reported 8% growth in revenues to ~$1.6 billion during 4Q17 as compared to ~$1.4 billion in 4Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How AstraZeneca’s Other Products Portfolio Performed in 4Q17

    AstraZeneca’s (AZN) other products portfolio reported revenues of ~$1.1 billion during 4Q17, a 17% decline in operating revenues.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Sanofi’s Generics and Consumer Healthcare Portfolios in 4Q17

    Sanofi’s consumer healthcare portfolio reported revenues of 1.2 billion euros in 4Q17, reflecting 51.8% growth in operating revenues compared to 4Q16.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Shingrix Could Be a Long-Term Growth Driver for GlaxoSmithKline

    On October 20, 2017, the U.S. Food and Drug Administration (or FDA) approved GlaxoSmithKline’s (GSK) Zoster vaccine recombinant and adjuvanted vaccine, Shingrix.

    By Margaret Patrick
  • uploads///Lucentis
    Company & Industry Overviews

    How Is Novartis’s Lucentis Positioned after 1H17?

    In 1H17, Novartis’s (NVS) Lucentis reported revenues of around $922 million, which is a ~1% decline on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Chart  ERx
    Company & Industry Overviews

    Performance of Sanofi’s Established Products in 2Q17

    Established products Sanofi’s (SNY) established products contributed over 29.5% of its total revenue in 2Q17. Established product revenue, which fell 2.3% at constant exchange rates in 2Q17, stood at 2.6 billion euros. Lower sales of Plavix, Lovenox, Allegra, Myslee, Lasix, and a few other drugs were substantially offset by strong performance by Renagel, Renvela, Aprovel, Synvisc, […]

    By Mike Benson
  • Market Realist Logo

    © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.